Hepatitis A Vaccine

Sayenna Uduman
Clinical & Epidemiological Background
Hepatitis A virus (HAV) is the most common cause of viral hepatitis worldwide. In resource-limited countries, most people are infected during the first decade of life, but incidence of disease attributable to HAV has declined significantly since Hepatitis A Vaccine was first licensed in Europe in 1991 and the United States in 1995.
Almost always childhood infection is anicteric and asymptomatic, resulting lifelong protective immunity. In contrast, infection acquired during adolescent and adult are symptomatic and typically lasts several weeks, with jaundice occurring in 70% or more; although 10% to 15% of symptomatic people have prolonged or relapsing disease lasting as long as 6 months. A member of the Picornaviridae family, HAV has only one serotype. Chronic infection does not occur. Fulminant hepatitis is rare but is more common in people with underlying liver disease.
Unlike hepatitis B (HBV) and C (HCV) viruses, HAV is spread primarily through the fecal-oral route, carried via the bloodstream to its primary target, the hepatocyte, where it replicates robustly but without causing much damage to the cells. Newly made virus is released via the bile ducts secreted into the intestines and stool. Being mostly asymptomatic and having longer fecal shedding of virus, both Infants and children have remained the primary reservoir of HAV and are a source of infection for vulnerable adults.
HAV infection is more likely to result in significant liver disease in individuals coinfected with HBV or HCV or HEV, patients waiting for or having undergone liver transplantation, pregnant women, and people infected with HIV infection. HAV has been identified as the most common cause of acute hepatitis and the disease may be prolonged for months and has a particularly high mortality rate in the presence of chronic liver disease. For these high-risk populations, not only is the acute infection more severe, but the immune response to HAV vaccination is relatively poor. Hence, it is imperative to vaccinate patients at special risk early, before they have suffered significant hepatic damage from their underlying disease.

• Personal hand hygiene ,
• Improved sanitation (eg, in food preparation and of water sources)
• Immunization with hepatitis A vaccine.
• Standard Immune globulin (IGIM) are recommended for post-exposure prophylaxis for unimmunized patients

Hepatitis A Vaccine Hepatitis A Vaccine 01/09/2001
Hepatitis A Vaccines (hepa Vaccines) >>
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0